Brass Bull Alerts
13K posts

Brass Bull Alerts
@MicroCapTweets
Experienced trader/consultant. Alert trade ideas, insight & client cos info. ALL OUR OPINION. Don't take stock! https://t.co/REI24v9xdI



$MAJI in October the company was awareded Orphan Drug Designation for its exosome-based GBM treatment also known as Glioblastoma multiforme. Only 11% of orphan drug designations are awarded at the preclinical stage. "Our breakthrough exosomal technology has the ability to deliver a wide range of therapeutics, including genetic material, into cells afflicted with cancer, such as GBM. The therapeutic technology presented in this orphan drug application is a method for using exosomes loaded with desired nucleic acids, in the effective treatment of GBM when combined with currently available standard anticancer therapy." They plan to work with investment bankers to expand and monetize the therapy. A product like this could bring in 10's of millions of dollars alone to the company. otcmarkets.com/stock/MAJI/new…




$MAJI currently owns a controlling stake in $LMMY which is a SEC-reporting stock trading at $0.49 per share - 10X MAJI current PPS. With the strategic alignment of the two entities, MAJI owns 51% of their restricted stock making them the controlling shareholder. Per their November 2025 PR this will be used to raise capital and ensure the funding is non-dilutive to MAJI shareholders. LMMY intends to begin the process to uplist to Nasdaq. otcmarkets.com/stock/MAJI/new…

@MicroCapTweets @SuperRobotGX $MAJI Amazing - everything they are announcing isn’t reflected in the stock price They are: > making acquisitions > tightening and protecting the share structure > rolling out patent protected new products > expanding into different sectors with same technology (Derm and CBD)

Exciting news for $MAJI: When our site is live! Anyone interested in joining our groundbreaking cancer screening study can now sign up directly online. Once enrolled, you’ll receive a comprehensive at-home collection kit with clear instructions for a seamless return. Your results will be delivered securely via email, and all data is strictly managed under HIPAA guidelines to ensure your privacy. Join us in advancing early detection!..more to come.





$MAJI — the telehealth company with which we are finalizing a definitive agreement — is currently renegotiating terms with 1,900 clinics to expand its role as sole distributor beyond testosterone. The existing testosterone program alone generates approximately $4 per script across an estimated 2,000 daily prescriptions, highlighting meaningful revenue potential with significant upside as the partnership broadens. #OTC

$MAJI currently owns a controlling stake in $LMMY which is a SEC-reporting stock trading at $0.49 per share - 10X MAJI current PPS. With the strategic alignment of the two entities, MAJI owns 51% of their restricted stock making them the controlling shareholder. Per their November 2025 PR this will be used to raise capital and ensure the funding is non-dilutive to MAJI shareholders. LMMY intends to begin the process to uplist to Nasdaq. otcmarkets.com/stock/MAJI/new…

$MAJI on top of the most recent update, the company released a roadmap late February where it went into detail not only the share cancellations but ongoing strategic developments in the works, with more to be added come April. Still pending is closing of definitive agreements to acquire 3 telehealth previously under LOI, closing an anticipated $100M deal as well as the launch of a new website. globenewswire.com/news-release/2…

$MAJI owns 51% of $LMMY ARB UPDATE after the recent OS reduction for MAJI OS: MAJI=37,750,959 LMMY=73,500,000 Current prices: MAJI= .042 LMMY= .489 Arb value diff for $MAJI .042 to .486 (11.5x diff) Currently 1:1 for stock price value w/ $LMMY Worth 11.5 times current price!


$MAJI worth keeping an eye on with recent news which started the chart reversal earlier last week and expected to close within 30 days from March 16th. Maji will make a one time payment of $147.5K which will allow the company to secure favorable financial restructuring outcomes. 🔥$200K promissory note cancellation 🔥Eliminate remaining balance tied to control block of preferred shares 🔥Nearly 6.3M shares of common stock cancelled and returned to treasury 🔥Allow the company to proceed with a clean, streamlined audit "By resolving this legacy dispute efficiently, Exousia Pro’s management team can now focus entirely on advancing its core clinical pipeline and expanding its telehealth initiatives without the distraction or financial overhang of litigation." otcmarkets.com/stock/MAJI/new…

Big news for $MAJI shareholders: We are nearing the execution of our first Definitive Agreement, covering two of our Telehealth acquisitions! To mark the occasion, we’re hosting a special session with @buffalofireside featuring the founder from these companies. This is a rare opportunity to hear directly from the visionary behind these two acquisitions, as well as about our integration strategy and the future of our telehealth ecosystem. Stay tuned for the official announcement—you won't want to miss this DD!...more to come.

Big news for $MAJI shareholders: We are nearing the execution of our first Definitive Agreement, covering two of our Telehealth acquisitions! To mark the occasion, we’re hosting a special session with @buffalofireside featuring the founder from these companies. This is a rare opportunity to hear directly from the visionary behind these two acquisitions, as well as about our integration strategy and the future of our telehealth ecosystem. Stay tuned for the official announcement—you won't want to miss this DD!...more to come.

$MAJI is officially NexTel Medical Corp! We are thrilled to announce our formal name change, reflecting a strategic evolution into the broader wellness and biotechnology space. While our identity is growing, we remain deeply rooted in our cutting-edge exosome technology, continuing the vital work on our cancer screening tests and premium wellness products. Integrating the telehealth sector presents a transformative opportunity to scale our operations and build a dedicated, in-house consumer base for our exosome-driven innovations. This is just the beginning. Our application to FINRA will be submitted shortly.—more major updates are on the horizon!


